Issue Date: August 18, 2014
GSK Eyes Development Of Ebola Vaccine
GlaxoSmithKline says it is in discussions with regulators about beginning Phase I clinical trials of an Ebola vaccine candidate. GSK acquired the product as part of its May 2013 purchase of the Swiss vaccines firm Okairos for $325 million. The British drugmaker says it is working with NIH’s Vaccine Research Center to advance development of what is now an early-stage candidate. It cautions that clinical development for a new vaccine can take 10 or more years and that accelerating the process is difficult.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society